Skip to main navigation

Main Nav

About Us
Scientific Platform
Our Pipeline
Career Opportunities
Investors & Media

Press Releases

IR Nav

Overview
Press Releases
Events
Presentations
Annual Reports
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
FAQs
Email Alerts
Investor Contact

Shareholder Tools

Press Releases

Year

Gritstone bio to Participate in Upcoming Investor Conferences

November 20, 2023

Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

November 8, 2023

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 7, 2023

Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine

October 11, 2023

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2023

Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023

October 4, 2023

Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million

September 27, 2023

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 13, 2023

Gritstone bio to Participate in Upcoming Investor Conferences

September 5, 2023

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 16, 2023

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

© 2023 Gritstone Bio |

Footer Links

Privacy Policy
Terms of Use
Cookie Policy
Contact

socials

Top